← Leaderboards
Jonathan B. Mitchem
Harry S. Truman Memorial Va Hospital
$0
Attributed
$0
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $0 · FY2019–24$1$1$1$0$0
'19
'20
'21
'22
'23
'24
Funding mix
By agency
VA$0 · 1
By mechanism
IK2$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Harry S. Truman Memorial Va Hospital
Same institution · by research overlap
- Sharad Khare$566,663
Others in their field
Other Emerging Leaders on “Cytotoxic T-Lymphocytes”
- Wilton B Williams · Duke University$11,406,665
- Deanna A Kulpa · Emory University$10,394,989
- Gaurav Das Gaiha · Massachusetts General Hospital$6,586,745
- Nilu Goonetilleke · Univ Of North Carolina Chapel Hill$6,073,977
- Michael Daniel Keller · Children'S Research Institute$4,910,377
- Todd Christopher Bradley · Children'S Mercy Hosp (Kansas City, Mo)$4,700,068
Research focus
Cytotoxic T-LymphocytesDendritic CellsAdvanced DiseaseCombined Modality TherapyAreaAntigensAffectCareerAntitumor ResponseCell DeathCell InjuryCell PhysiologyCell TypeChemotherapyChemotherapy-Oncologic ProcedureCancer DiagnosisClinical TrialsClinical Trials DesignCell CountColon CarcinomaColorectal CancerCombination Drug TherapyCombination ImmunotherapyDesign
Grant awards (6)
Optimizing anti-tumor immunity for maximal therapeutic efficacy in Colorectal Cancer$0
IK2 · FY2024 · VA · contact PI
Optimizing anti-tumor immunity for maximal therapeutic efficacy in Colorectal Cancer$0
IK2 · FY2023 · VA · contact PI
Optimizing anti-tumor immunity for maximal therapeutic efficacy in Colorectal Cancer$0
IK2 · FY2022 · VA · contact PI
Optimizing anti-tumor immunity for maximal therapeutic efficacy in Colorectal Cancer$0
IK2 · FY2021 · VA · contact PI
Optimizing anti-tumor immunity for maximal therapeutic efficacy in Colorectal Cancer$0
IK2 · FY2020 · VA · contact PI
Optimizing anti-tumor immunity for maximal therapeutic efficacy in Colorectal Cancer$0
IK2 · FY2019 · VA · contact PI